When doing open-heart surgery, the surgeon needs a still heart and lungs to work. The patient still needs oxygen circulated through the bloodstream to survive. Thus, cardiovascular perfusionists (also ...
GlobalData on MSN
TransMedics receives IDE approval from FDA for OCS Heart trial
The total number of patients enrolled across both parts is anticipated to exceed 650.
A new medical technology expected to be on the market in 2027 is poised to help patients in middle America have greater ...
TransMedics Group (NasdaqGM:TMDX) received full FDA approval for its Next-Generation OCS ENHANCE Heart trial. The decision ...
TransMedics TMDX recently announced that it has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its next-generation OCS ENHANCE Heart trial, eliminating a key ...
The emerging advantages of positron-emission tomography (PET) myocardial perfusion imaging (MPI) for coronary artery disease (CAD) diagnosis and assessment of cardiovascular event risk has prompted ...
TransMedics (Nasdaq:TMDX) received FDA investigational device exemption (IDE) for its next-generation OCS ENHANCE Heart trial.
Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon emission ...
The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease, ...
New Clinical Indications Statement Expands Recommendations for Cardiac PET and Myocardial Blood Flow Quantification Based on the clinical and scientific evidence now available, there are no clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results